Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fondazione Italiana Linfomi - ETS
Prospective, multicentre phase II study with R-CHOP- 14 or R-CHOP-21 \& consolidation PET-oriented radiotherapy (RT) in diffuse large B cell lymphoma (DLBCL) patients with low risk profile according to age-adjusted IPI (0 with bulky or 1)
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histological diagnosis of DLBCL (CD20+), follicular lymphoma grade IIIB, T-cell rich large B cell lymphoma
Age 18-80 years (patients \>70 years old: FIT according to VGM evaluation).
aaIPI=1 +/- bulky and aaIPI=0 with bulky (\>7.5 cm)
ECOG-PS \< 3 unless due to lymphoma
Ventricular ejection fraction ≥ 50%
Pulmonary, renal and hepatic tests within normal range
Negative HIV and HBV tests. In case of HBcAb positive and HBsAb +/-, which is indicative of a past infection (occult carriers) the subject can be included, but antiviral prophylaxis with lamivudine must be given from the beginning of treatment until 12 months after treatment completion. Anti-HCV positive patients can be included in the absence of viral replication (HVR-RNA absent or less than 500 copies/ml.
Written informed consent
Life-expectancy \> 3 months
HIV positivity
significant cardiopathy
You may not be if
T-cell lymphoma
Follicular lymphoma (grade I, II, IIIA), marginal zone and mantle lymphoma
PS\> 3 (if not due to lymphoma)
Age-adjusted IPI = 0 in the absence of bulky disease
